Document is current
Any future updates will be listed below
-
Authors
Estofolete, Cassia F.
Saivish, Marielena V.
Nogueira, Maurício L.
Vasilakis, Nikos
-
Funding
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (2022/09229-0)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2020/12875-5 and 2023/09590-7)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2013/21719-3 and 2022/03645-1)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (465425/2014–3 and 405786/2022–0)
National Institute of Allergy and Infectious Diseases (U01AI151807)
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 3 February 2026
First Online: 14 February 2026
Competing interests
: C.F.E. and M.L.N. report research funding from Instituto Butantan related to the Brazilian Phase III dengue vaccine study and Takeda as an investigator in a clinical trial. M.L.N. is an Associate Editor of npj Viruses. M.L.N. was not involved in the journal’s review of, or decisions related to, this manuscript. The remaining authors declare no competing financial or non-financial interests.
